Sodium phenylbutyrate

Sodium phenylbutyrate is an orphan drug, marketed by Ucyclyd Pharma (Hunt Valley, USA) under the trade name Buphenyl® and by Orphan Europe (France) as Ammonaps®.

Additional recommended knowledge

How to quickly check pipettes?

Weighing the right way

Recognize and detect the effects of electrostatic charges on your balance

It has been used to treat urea cycle disorders.^[1]

Scanadinavian Formulas, Inc. Sellersville, PA supplies Sodium Phenylbutyrate worldwide for clinical trials.

Metabolism

Phenylbutyrate is a prodrug. In the human body it is metabolized by beta-oxidation to phenylacetate.

Phenylacetate conjugate with glutamine to phenylacetylglutamine, that is eliminated with the urine.

Research

Sodium phenylbutyrate is also under investigation for the treatment of some sickle-cell disorders (Blood Products Plasma Expanders and Haemostatics) and for use as a potential differentiation-inducing agent in malignant glioma and acute myeloid leukaemia.

PBA has been associated with longer lifespans in Drosophila.^[2]

References

1. ^ Batshaw ML, MacArthur RB, Tuchman M (2001). "Alternative pathway therapy for urea cycle disorders: twenty years later". J. Pediatr. 138 (1 Suppl): S46-54; discussion S54-5. PMID 11148549.
2. ^ Kang HL, Benzer S, Min KT (2002). "Life extension in Drosophila by feeding a drug". Proc. Natl. Acad. Sci. U.S.A. 99 (2): 838-43. doi:10.1073/pnas.022631999. PMID 11792861.